Regeneron Pharmaceuticals, Inc.
George L Sing (Director) sells REGN shares
AI-generated summary
Director George L Sing exercised options for 15,269 shares of Common Stock for $5,783,369.75 and sold 21,129 shares for $20,376,358.34. Following the transactions, the insider directly held 25,147 shares.
Key facts
- Insider
- George L Sing · Director
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | M · exercise or conversion of a derivative | +7,830 | $376.69 | $2,949,482.70 | 38,837 | Direct |
| Nov 2, 2026 | M · exercise or conversion of a derivative | +7,439 | $380.95 | $2,833,887.05 | 46,276 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F1 | −1,224 | $960.57 | $1,175,737.68 | 45,052 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F2 | −540 | $961.85 | $519,399.00 | 44,512 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F3 | −2,522 | $962.61 | $2,427,702.42 | 41,990 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F4 | −4,338 | $963.47 | $4,179,532.86 | 37,652 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F5 | −2,670 | $964.57 | $2,575,401.90 | 34,982 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F6 | −7,073 | $965.38 | $6,828,132.74 | 27,909 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F7 | −1,522 | $966.27 | $1,470,662.94 | 26,387 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F8 | −1,040 | $967.07 | $1,005,752.80 | 25,347 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F9 | −200 | $970.18 | $194,036.00 | 25,147 | Direct |
| Nov 2, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F10 | −7,830 | $0.00 | $0.00 | 0 | Direct |
| Nov 2, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F10 | −7,439 | $0.00 | $0.00 | 0 | Direct |
Footnotes
- F1 Represents volume-weighted average price of sales of 1,224 shares of Company stock on November 2, 2026 at prices ranging from $960.03 to $960.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
- F2 Represents volume-weighted average price of sales of 540 shares of Company stock on November 2, 2026 at prices ranging from $961.76 to $961.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
- F3 Represents volume-weighted average price of sales of 2,522 shares of Company stock on November 2, 2026 at prices ranging from $962.07 to $962.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
- F4 Represents volume-weighted average price of sales of 4,338 shares of Company stock on November 2, 2026 at prices ranging from $963.00 to $963.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
- F5 Represents volume-weighted average price of sales of 2,670 shares of Company stock on November 2, 2026 at prices ranging from $964.10 to $964.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
- F6 Represents volume-weighted average price of sales of 7,073 shares of Company stock on November 2, 2026 at prices ranging from $965.00 to $965.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
- F7 Represents volume-weighted average price of sales of 1,522 shares of Company stock on November 2, 2026 at prices ranging from $966.02 to $966.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
- F8 Represents volume-weighted average price of sales of 1,040 shares of Company stock on November 2, 2026 at prices ranging from $967.00 to $967.26. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
- F9 Represents volume-weighted average price of sales of 200 shares of Company stock on November 2, 2026 at prices ranging from $970.16 to $970.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
- F10 The stock option vested in three equal annual installments, commencing one year after the date of grant.
More REGN filings
- 144
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
- 144
Filed Nov 4, 2026
- 4
Filed Nov 3, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.